{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T02:12:51Z","timestamp":1791339171099,"version":"4.3.1"},"reference-count":89,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,8,18]],"date-time":"2015-08-18T00:00:00Z","timestamp":1439856000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["IG-14258"],"award-info":[{"award-number":["IG-14258"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["IG-13233"],"award-info":[{"award-number":["IG-13233"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.canlet.2015.08.007","type":"journal-article","created":{"date-parts":[[2015,8,13]],"date-time":"2015-08-13T18:40:14Z","timestamp":1439491214000},"page":"37-44","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":126,"title":["Post-transplant lymphoproliferative disorders: From epidemiology to pathogenesis-driven treatment"],"prefix":"10.1016","volume":"369","author":[{"given":"Maria Raffaella","family":"Petrara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Giunco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Serraino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Dolcetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"De Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2015.08.007_bib0010","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0140-6736(84)90994-2","article-title":"Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy","volume":"1","author":"Starzl","year":"1984","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2015.08.007_bib0015","doi-asserted-by":"crossref","first-page":"150835","DOI":"10.1155\/2013\/150835","article-title":"Molecular pathogenesis of B-cell posttransplant lymphoproliferative disorder: what do we know so far?","volume":"2013","author":"Morscio","year":"2013","journal-title":"Clin. Dev. Immunol"},{"key":"10.1016\/j.canlet.2015.08.007_bib0020","author":"Global Observatory on Donation and Transplantation"},{"key":"10.1016\/j.canlet.2015.08.007_bib0025","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1001\/jama.296.23.2823","article-title":"Cancer incidence before and after kidney transplantation","volume":"296","author":"Vajdic","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.canlet.2015.08.007_bib0030","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1001\/jama.2011.1592","article-title":"Spectrum of cancer risk among US solid organ transplant recipients","volume":"306","author":"Engels","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.canlet.2015.08.007_bib0035","series-title":"Post-Transplant Lymphoproliferative Disorders. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2008"},{"key":"10.1016\/j.canlet.2015.08.007_bib0040","doi-asserted-by":"crossref","first-page":"230173","DOI":"10.1155\/2012\/230173","article-title":"Posttransplant lymphoproliferative disorders","volume":"2012","author":"Ibrahim","year":"2012","journal-title":"Adv. Hematol"},{"key":"10.1016\/j.canlet.2015.08.007_bib0045","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/978-3-642-38965-8_10","article-title":"Prevention and treatment for Epstein-Barr virus infection and related cancers","volume":"193","author":"Smets","year":"2014","journal-title":"Recent Results Cancer Res"},{"key":"10.1016\/j.canlet.2015.08.007_bib0050","first-page":"39","article-title":"Features, predictors and prognosis of lymphoproliferative disorders post-liver transplantation regarding disease presentation time: report from the PTLD. Int. survey","volume":"16","author":"Izadi","year":"2011","journal-title":"Ann. Transplant"},{"key":"10.1016\/j.canlet.2015.08.007_bib0055","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ejca.2012.09.013","article-title":"Immunosuppression and Cancer Study Group. Risk of de novo cancers after transplantation: results from a cohort of 7217 kidney transplant recipients, Italy 1997\u20132009","volume":"49","author":"Piselli","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.canlet.2015.08.007_bib0060","doi-asserted-by":"crossref","first-page":"3592","DOI":"10.1016\/j.transproceed.2013.10.030","article-title":"Incidence of post-transplantation lymphoproliferative disease in Andalusia (1990\u20132009)","volume":"45","author":"Govantes","year":"2013","journal-title":"Transplant. Proc"},{"key":"10.1016\/j.canlet.2015.08.007_bib0065","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/tri.12328","article-title":"Comparative analysis of post-transplant lymphoproliferative disorder after kidney transplantation versus hematopoietic stem cell transplantation","volume":"27","author":"Yoon","year":"2014","journal-title":"Transpl. Int"},{"key":"10.1016\/j.canlet.2015.08.007_bib0070","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/ajh.21911","article-title":"Risk factors for early-onset and late-onset post-transplant lymphoproliferative disorder in kidney recipients in the United States","volume":"86","author":"Quinlan","year":"2011","journal-title":"Am. J. Hematol"},{"key":"10.1016\/j.canlet.2015.08.007_bib0075","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1093\/ndt\/gfr769","article-title":"Impact of Epstein-Barr virus donor and recipient serostatus on the incidence of post-transplant lymphoproliferative disorder in kidney transplant recipients","volume":"27","author":"Sampaio","year":"2012","journal-title":"Nephrol. Dial. Transplant"},{"key":"10.1016\/j.canlet.2015.08.007_bib0080","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1399-0012.2010.01392.x","article-title":"Post-transplant lymphoproliferative disorders: clinicopathological analysis of 43 cases in a single center, 1990\u20132009","volume":"26","author":"Yoon","year":"2012","journal-title":"Clin. Transplant"},{"key":"10.1016\/j.canlet.2015.08.007_bib0085","first-page":"2383","article-title":"Post-transplant lymphoproliferative disorders in liver transplanted patients: a single-centre experience","volume":"30","author":"Marino","year":"2010","journal-title":"Anticancer Res"},{"key":"10.1016\/j.canlet.2015.08.007_bib0090","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1016\/j.transproceed.2013.07.050","article-title":"De novo malignancies following liver transplantation: results from a multicentric study in central and southern Italy, 1990\u20132008","volume":"45","author":"Ettorre","year":"2013","journal-title":"Transplant. Proc"},{"key":"10.1016\/j.canlet.2015.08.007_bib0095","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/ctr.12152","article-title":"Post-transplant lymphoproliferative disorder in adult liver transplant recipients: a South American multicenter experience","volume":"27","author":"Mendizabal","year":"2013","journal-title":"Clin. Transplant"},{"key":"10.1016\/j.canlet.2015.08.007_bib0100","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1136\/jclinpath-2012-201139","article-title":"Post-transplant lymphoproliferative disorders in liver transplant recipients: a clinicopathological study","volume":"66","author":"Lo","year":"2013","journal-title":"J. Clin. Pathol"},{"key":"10.1016\/j.canlet.2015.08.007_bib0105","doi-asserted-by":"crossref","first-page":"e310","DOI":"10.1097\/MD.0000000000000310","article-title":"Post-transplant malignancy in liver transplantation: a single center experience","volume":"93","author":"Hsiao","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.canlet.2015.08.007_bib0110","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.3109\/10428194.2010.492063","article-title":"Post-transplant lymphoproliferative disorder after adult-to-adult living donor liver transplant: case series and review of literature","volume":"51","author":"Kataoka","year":"2010","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.canlet.2015.08.007_bib0115","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/nrc1452","article-title":"Epstein-Barr virus: 40 years on","volume":"4","author":"Young","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2015.08.007_bib0120","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3389\/fmicb.2013.00311","article-title":"Epstein-Barr virus-driven lymphomagenesis in the context of human immunodeficiency virus type 1 infection","volume":"4","author":"Petrara","year":"2013","journal-title":"Front. Microbiol"},{"key":"10.1016\/j.canlet.2015.08.007_bib0125","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/1469-0691.12534","article-title":"ESCMID Study Group of Infection in Compromised Hosts. Epstein-Barr virus-related post-transplant lymphoproliferative disorder in solid organ transplant recipients","volume":"Suppl 7","author":"San-Juan","year":"2014","journal-title":"Clin. Microbiol. Infect"},{"key":"10.1016\/j.canlet.2015.08.007_bib0130","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2012.43.2344","article-title":"Post-transplantation lymphoproliferative disorder after kidney transplantation: report of a nationwide French registry and the development of a new prognostic score","volume":"31","author":"Caillard","year":"2013","journal-title":"J. Clin. Oncol"},{"key":"10.1016\/j.canlet.2015.08.007_bib0135","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.autrev.2007.02.012","article-title":"B lymphocytes and Epstein-Barr virus: the lesson of post-transplant lymphoproliferative disorders","volume":"7","author":"Dolcetti","year":"2007","journal-title":"Autoimmun. Rev"},{"key":"10.1016\/j.canlet.2015.08.007_bib0140","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.4103\/1319-2442.121270","article-title":"Ultra-early onset post-transplantation lymphoproliferative disease","volume":"24","author":"Khedmat","year":"2013","journal-title":"Saudi J. Kidney Dis. Transpl"},{"key":"10.1016\/j.canlet.2015.08.007_bib0145","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1093\/ndt\/gfs476","article-title":"Late-onset post-transplantation lymphoproliferative disorders after kidney transplantation: a monocentric study over three decades","volume":"28","author":"Michonneau","year":"2013","journal-title":"Nephrol. Dial. Transplant"},{"key":"10.1016\/j.canlet.2015.08.007_bib0150","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/j.1399-0012.2011.01593.x","article-title":"Post-transplant lymphoproliferative diseases in Asian solid organ transplant recipients: late onset and favorable response to treatment","volume":"26","author":"Chan","year":"2012","journal-title":"Clin. Transplant"},{"key":"10.1016\/j.canlet.2015.08.007_bib0155","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1097\/TP.0b013e318276a237","article-title":"Epidemiology of posttransplantation lymphoproliferative disorder in adult renal transplant recipients","volume":"95","author":"Morton","year":"2013","journal-title":"Transplantation"},{"key":"10.1016\/j.canlet.2015.08.007_bib0160","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3389\/fmicb.2011.00005","article-title":"Epstein-Barr virus, the immune system, and associated diseases","volume":"2","author":"Chen","year":"2011","journal-title":"Front. Microbiol"},{"key":"10.1016\/j.canlet.2015.08.007_bib0165","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/med.20211","article-title":"Telomere\/telomerase interplay in virus-driven and virus-independent lymphomagenesis: pathogenic and clinical implications","volume":"32","author":"Dolcetti","year":"2012","journal-title":"Med. Res. Rev"},{"key":"10.1016\/j.canlet.2015.08.007_bib0170","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/ijc.22661","article-title":"hTERT inhibits the Epstein-Barr virus lytic cycle and promotes the proliferation of primary B lymphocytes: implications for EBV-driven lymphomagenesis","volume":"121","author":"Terrin","year":"2007","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2015.08.007_bib0175","doi-asserted-by":"crossref","first-page":"10175","DOI":"10.1128\/JVI.00321-08","article-title":"Latent membrane protein 1 of Epstein-Barr virus activates the hTERT promoter and enhances telomerase activity in B lymphocytes","volume":"82","author":"Terrin","year":"2008","journal-title":"J. Virol"},{"key":"10.1016\/j.canlet.2015.08.007_bib0180","doi-asserted-by":"crossref","first-page":"e1774","DOI":"10.1038\/cddis.2015.145","article-title":"Cross talk between EBV and telomerase: the role of TERT and NOTCH2 in the switch of latent\/lytic cycle of the virus","volume":"6","author":"Giunco","year":"2015","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.canlet.2015.08.007_bib0185","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1158\/1078-0432.CCR-12-2537","article-title":"hTERT inhibition triggers Epstein-Barr virus lytic cycle and apoptosis in immortalized and transformed B-cells: a basis for new therapies","volume":"19","author":"Giunco","year":"2013","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.canlet.2015.08.007_bib0190","doi-asserted-by":"crossref","first-page":"13993","DOI":"10.1128\/JVI.79.22.13993-14003.2005","article-title":"Epstein-Barr virus lytic infection contributes to lymphoproliferative disease in a SCID mouse model","volume":"79","author":"Hong","year":"2005","journal-title":"J. Virol"},{"key":"10.1016\/j.canlet.2015.08.007_bib0195","first-page":"370516","article-title":"Epstein-Barr virus and systemic lupus erythematosus","author":"Draborg","year":"2012","journal-title":"Clin. Dev. Immunol"},{"key":"10.1016\/j.canlet.2015.08.007_bib0200","doi-asserted-by":"crossref","first-page":"13984","DOI":"10.1128\/JVI.79.22.13984-13992.2005","article-title":"Epstein-Barr virus lytic infection is required for efficient production of the angiogenesis factor vascular endothelial growth factor in lymphoblastoid cell lines","volume":"79","author":"Hong","year":"2005","journal-title":"J. Virol"},{"key":"10.1016\/j.canlet.2015.08.007_bib0205","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1056\/NEJMcibr1404664","article-title":"Parallels between cancer and infectious disease","volume":"371","author":"Hotchkiss","year":"2014","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.canlet.2015.08.007_bib0210","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.4049\/jimmunol.147.9.2922","article-title":"Recombinant gp120 specifically enhances tumor necrosis factor-alpha production and Ig secretion in B lymphocytes from HIV-infected individuals but not from seronegative donors","volume":"147","author":"Rieckmann","year":"1991","journal-title":"J. Immunol"},{"key":"10.1016\/j.canlet.2015.08.007_bib0215","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1006\/cimm.1995.1210","article-title":"Induction of IL-6 and IL-10 production by recombinant HIV-1 envelope glycoprotein 41 (gp41) in the THP-1 human monocytic cell line","volume":"165","author":"Takeshita","year":"1995","journal-title":"Cell. Immunol"},{"key":"10.1016\/j.canlet.2015.08.007_bib0220","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1038\/nm.1871","article-title":"Divergent TLR7 and TLR9 signaling and type I interferon production distinguish pathogenic and nonpathogenic AIDS virus infections","volume":"14","author":"Mandl","year":"2008","journal-title":"Nat. Med"},{"key":"10.1016\/j.canlet.2015.08.007_bib0225","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1097\/COH.0b013e32833f327e","article-title":"Cancer biomarkers in HIV patients","volume":"5","author":"Ambinder","year":"2010","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.canlet.2015.08.007_bib0230","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1158\/1055-9965.EPI-11-0037","article-title":"B-cell stimulatory cytokines and markers of immune activation are elevated several years prior to the diagnosis of systemic AIDS-associated non-Hodgkin B-cell lymphoma","volume":"20","author":"Breen","year":"2011","journal-title":"Cancer Epidemiol. Biomarkers Prev"},{"key":"10.1016\/j.canlet.2015.08.007_bib0235","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1111\/j.1462-5822.2007.00937.x","article-title":"Immune activation suppresses initiation of lytic Epstein-Barr virus infection","volume":"9","author":"Ladell","year":"2007","journal-title":"Cell. Microbiol"},{"key":"10.1016\/j.canlet.2015.08.007_bib0240","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jcv.2011.12.013","article-title":"Epstein-Barr virus load and immune activation in human immunodeficiency virus type 1-infected patients","volume":"53","author":"Petrara","year":"2012","journal-title":"J. Clin. Virol"},{"key":"10.1016\/j.canlet.2015.08.007_bib0245","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/rmv.582","article-title":"Measuring Epstein-Barr virus (EBV) load: the significance and application for each EBV-associated disease","volume":"18","author":"Kimura","year":"2008","journal-title":"Rev. Med. Virol"},{"key":"10.1016\/j.canlet.2015.08.007_bib0250","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.1182\/blood-2009-07-143545","article-title":"How I treat EBV lymphoproliferation","volume":"114","author":"Heslop","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2015.08.007_bib0255","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1182\/blood.V96.13.4055","article-title":"Characterization of Epstein\u2013Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical response","volume":"96","author":"Yang","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2015.08.007_bib0260","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1097\/00007890-200207270-00009","article-title":"Persistent Epstein\u2013Barr virus infection: unrestricted latent and lytic viral gene expression in healthy immunosuppressed transplant recipients","volume":"74","author":"Hopwood","year":"2002","journal-title":"Transplantation"},{"key":"10.1016\/j.canlet.2015.08.007_bib0265","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1046\/j.1365-2141.2001.02789.x","article-title":"Molecular quantification of viral load in plasma allows for fast and accurate prediction of response to therapy of Epstein-Barr virus-associated lymphoproliferative disease after allogeneic stem cell transplantation","volume":"113","author":"van Esser","year":"2001","journal-title":"Br. J. Haematol"},{"key":"10.1016\/j.canlet.2015.08.007_bib0270","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1128\/JCM.35.6.1612-1615.1997","article-title":"Use of quantitative competitive PCR to measure Epstein-Barr virus genome load in the peripheral blood of pediatric transplant patients with lymphoproliferative disorders","volume":"35","author":"Rowe","year":"1997","journal-title":"J. Clin. Microbiol"},{"key":"10.1016\/j.canlet.2015.08.007_bib0275","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1097\/00007890-199812270-00012","article-title":"Serial measurement of Epstein-Barr viral load in peripheral blood in pediatric liver transplant recipients during treatment for posttransplant lymphoproliferative disease","volume":"66","author":"Green","year":"1998","journal-title":"Transplantation"},{"key":"10.1016\/j.canlet.2015.08.007_bib0280","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1386-6532(03)00077-5","article-title":"A semiquantitative PCR method (SQ-PCR) to measure Epstein-Barr virus (EBV) load: its application in transplant patients","volume":"28","author":"Fellner","year":"2003","journal-title":"J. Clin. Virol"},{"key":"10.1016\/j.canlet.2015.08.007_bib0285","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1080\/10428190400027837","article-title":"Epstein-Barr viral load, interleukin-6 and interleukin-10 levels in post-transplant lymphoproliferative disease: a nested case-control study in a renal transplant cohort","volume":"46","author":"Baiocchi","year":"2005","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.canlet.2015.08.007_bib0290","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/jmv.21096","article-title":"Monitoring of Epstein-Barr virus load after hematopoietic stem cell transplantation for early intervention in post-transplant lymphoproliferative disease","volume":"80","author":"Meerbach","year":"2008","journal-title":"J. Med. Virol"},{"key":"10.1016\/j.canlet.2015.08.007_bib0295","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1186\/1743-422X-8-421","article-title":"Post-transplant lymphoproliferative disorders and Epstein-Barr virus DNAemia in a cohort of lung transplant recipients","volume":"8","author":"Baldanti","year":"2011","journal-title":"Virol. J."},{"key":"10.1016\/j.canlet.2015.08.007_bib0300","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S1525-1578(10)60637-X","article-title":"Predictive value of quantitative PCR-based viral burden analysis for eight human herpesviruses in pediatric solid organ transplant patients","volume":"2","author":"Bai","year":"2000","journal-title":"J. Mol. Diagn"},{"key":"10.1016\/j.canlet.2015.08.007_bib0305","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1182\/blood.V97.5.1165","article-title":"Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients","volume":"97","author":"Stevens","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2015.08.007_bib0310","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1034\/j.1399-0012.2002.1o112.x","article-title":"Significance of serial real-time PCR monitoring of EBV genome load in living donor liver transplantation","volume":"16","author":"Matsukura","year":"2002","journal-title":"Clin. Transplant"},{"key":"10.1016\/j.canlet.2015.08.007_bib0315","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/j.1399-0012.2012.01608.x","article-title":"Quantitative Epstein-Barr virus shedding and its correlation with the risk of post-transplant lymphoproliferative disorder","volume":"26","author":"Holman","year":"2012","journal-title":"Clin. Transplant"},{"key":"10.1016\/j.canlet.2015.08.007_bib0320","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1309\/AJCP9WYEXKOL9YUV","article-title":"Pattern analysis of Epstein-Barr virus viremia and its significance in the evaluation of organ transplant patients suspected of having posttransplant lymphoproliferative disorders","volume":"141","author":"Cho","year":"2014","journal-title":"Am. J. Clin. Pathol"},{"key":"10.1016\/j.canlet.2015.08.007_bib0325","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1086\/522531","article-title":"Epstein-Barr viral load and disease prediction in a large cohort of allogeneic stem cell transplant recipients","volume":"45","author":"Aalto","year":"2007","journal-title":"Clin. Infect. Dis"},{"key":"10.1016\/j.canlet.2015.08.007_bib0330","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1182\/blood.V83.9.2715.2715","article-title":"Direct correlation between the load of Epstein\u2013Barr virus-infected lymphocytes in the peripheral blood of pediatric transplant patients and risk of lymphoproliferative disease","volume":"83","author":"Savoie","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2015.08.007_bib0335","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1182\/blood.V92.10.3977","article-title":"Semiquantitative Epstein\u2013Barr virus polymerase chain reaction analysis of peripheral blood from organ transplant patients and risk for the development of lymphoproliferative disease","volume":"92","author":"Lucas","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2015.08.007_bib0340","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/S1473-3099(07)70159-7","article-title":"Viral dynamics in transplant patients: implications for disease","volume":"7","author":"Funk","year":"2007","journal-title":"Lancet Infect. Dis"},{"key":"10.1016\/j.canlet.2015.08.007_bib0345","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jcv.2010.12.002","article-title":"Multicenter comparative study of Epstein-Barr virus DNA quantification for virological monitoring in transplanted patients","volume":"50","author":"Abbate","year":"2011","journal-title":"J. Clin. Virol"},{"key":"10.1016\/j.canlet.2015.08.007_bib0350","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/BF02981956","article-title":"Quantitative monitoring of circulating Epstein-Barr virus DNA for predicting the development of posttransplantation lymphoproliferative disease","volume":"73","author":"Ogha","year":"2001","journal-title":"Int. J. Hematol"},{"key":"10.1016\/j.canlet.2015.08.007_bib0355","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1399-3046.2005.00404.x","article-title":"Epstein-Barr viremia levels after pediatric liver transplantation as measured by real-time polymerase chain reaction","volume":"10","author":"Kullberg-Lindh","year":"2006","journal-title":"Pediatr. Transplant"},{"key":"10.1016\/j.canlet.2015.08.007_bib0360","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1034\/j.1399-3046.2002.02029.x","article-title":"Epstein-Barr virus-related lymphoproliferation in children after liver transplant: role of immunity, diagnosis, and management","volume":"6","author":"Smets","year":"2002","journal-title":"Pediatr. Transplant"},{"key":"10.1016\/j.canlet.2015.08.007_bib0365","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/j.1399-3046.2012.01656.x","article-title":"Emerging therapeutic strategies for Epstein-Barr virus+ post-transplant lymphoproliferative disorder","volume":"16","author":"Hatton","year":"2012","journal-title":"Pediatr. Transplant"},{"key":"10.1016\/j.canlet.2015.08.007_bib0370","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1182\/blood-2005-01-0377","article-title":"Efficacy and safety of rituximab in B-cell posttransplantation lymphoproliferative disorders: Results of a prospective multicenter phase 2 study","volume":"107","author":"Choquet","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2015.08.007_bib0375","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/j.1600-6143.2005.01211.x","article-title":"Treatment of PTLD with rituximab or chemotherapy","volume":"6","author":"Elstrom","year":"2006","journal-title":"Am. J. Transplant"},{"key":"10.1016\/j.canlet.2015.08.007_bib0380","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/j.1399-3046.2010.01370.x","article-title":"Post-transplant lymphoproliferative disorder in children: Recent outcomes and response to dual rituximab\/low-dose chemotherapy combination","volume":"14","author":"Gupta","year":"2010","journal-title":"Pediatr. Transplant"},{"key":"10.1016\/j.canlet.2015.08.007_bib0385","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1399-3062.2009.00411.x","article-title":"Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases","volume":"11","author":"Styczynski","year":"2009","journal-title":"Transpl. Infect. Dis"},{"key":"10.1016\/j.canlet.2015.08.007_bib0390","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/nrclinonc.2012.111","article-title":"T-cell therapy in the treatment of post-transplant lymphoproliferative disease","volume":"9","author":"Bollard","year":"2012","journal-title":"Nat. Rev. Clin. Oncol"},{"key":"10.1016\/j.canlet.2015.08.007_bib0395","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1200\/JCO.2013.51.5304","article-title":"Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr Virus latent membrane proteins","volume":"32","author":"Bollard","year":"2014","journal-title":"J. Clin. Oncol"},{"key":"10.1016\/j.canlet.2015.08.007_bib0400","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1097\/00007890-199812270-00006","article-title":"Prevention and preemptive therapy of post-transplant lymphoproliferative disease in pediatric liver recipients","volume":"66","author":"McDiarmid","year":"1998","journal-title":"Transplantation"},{"key":"10.1016\/j.canlet.2015.08.007_bib0405","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1111\/j.1600-6143.2005.01115.x","article-title":"Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients","volume":"5","author":"Funch","year":"2005","journal-title":"Am. J. Transplant"},{"key":"10.1016\/j.canlet.2015.08.007_bib0410","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1002\/lt.21498","article-title":"Efficacy and safety of valganciclovir in liver-transplanted children infected with Epstein-Barr virus","volume":"14","author":"Hierro","year":"2008","journal-title":"Liver Transpl"},{"key":"10.1016\/j.canlet.2015.08.007_bib0415","first-page":"1485","article-title":"Induction of lytic Epstein-Barr virus (EBV) infection in EBV-associated malignancies using adenovirus vectors in vitro and in vivo","volume":"59","author":"Westphal","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.canlet.2015.08.007_bib0420","first-page":"1920","article-title":"Chemotherapy induces lytic EBV replication and confers ganciclovir susceptibility to EBV-positive epithelial cell tumors","volume":"62","author":"Feng","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.canlet.2015.08.007_bib0425","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1093\/jnci\/djh313","article-title":"Reactivation of latent Epstein-Barr virus by methotrexate: a potential contributor to methotrexate-associated lymphomas","volume":"96","author":"Feng","year":"2004","journal-title":"J. Natl Cancer Inst"},{"key":"10.1016\/j.canlet.2015.08.007_bib0430","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1158\/1078-0432.CCR-09-2424","article-title":"Viral response to chemotherapy in endemic burkitt lymphoma","volume":"16","author":"Tang","year":"2010","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.canlet.2015.08.007_bib0435","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1128\/AAC.45.7.2082-2091.2001","article-title":"Induction of Epstein-Barr virus kinases to sensitize tumor cells to nucleoside analogues","volume":"45","author":"Moore","year":"2001","journal-title":"Antimicrob. Agents Chemother"},{"key":"10.1016\/j.canlet.2015.08.007_bib0440","doi-asserted-by":"crossref","first-page":"8762","DOI":"10.1158\/0008-5472.CAN-06-1006","article-title":"Valproic acid enhances the efficacy of chemotherapy in EBV-positive tumors by increasing lytic viral gene expression","volume":"66","author":"Feng","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.canlet.2015.08.007_bib0445","doi-asserted-by":"crossref","first-page":"6297","DOI":"10.1182\/blood-2011-01-332379","article-title":"Bortezomib induction of C\/EBP\u03b2 mediates Epstein-Barr virus lytic activation in Burkitt lymphoma","volume":"117","author":"Shirley","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2015.08.007_bib0450","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1182\/blood-2006-01-024703","article-title":"A phase 1\/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies","volume":"109","author":"Perrine","year":"2007","journal-title":"Blood"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383515005364?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383515005364?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,13]],"date-time":"2023-08-13T04:25:54Z","timestamp":1691900754000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383515005364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":89,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S0304383515005364"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2015.08.007","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Post-transplant lymphoproliferative disorders: From epidemiology to pathogenesis-driven treatment","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2015.08.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}